Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4694589 | 0.80 | ALDH1A1 (0.72) | ALDH1A1HTTKDM4ETDP1GAA | |
| SCHEMBL9734743 | 0.80 | KDM4E (0.45) | ALDH1A1HTTKDM4ETDP1GAA | |
| SCHEMBL10008027 | 0.78 | ALDH1A1 (0.59) | ALDH1A1HTTKDM4ETDP1GAA | |
| SCHEMBL2107188 | 0.78 | ALDH1A1 (0.59) | ALDH1A1HTTKDM4ETDP1GAA | |
| SCHEMBL30340989 | 0.78 | ALDH1A1 (0.67) | ALDH1A1HTTKDM4ETDP1GAA | |
| SCHEMBL13293320 | 0.77 | ALDH1A1 (1.00) | ALDH1A1HTTKDM4ETDP1GAA | |
| SCHEMBL7735651 | 0.77 | KDM4E (0.62) | ALDH1A1KDM4ETDP1GAAHRH3 | |
| SCHEMBL6568587 | 0.77 | POLB (0.62) | ALDH1A1HTTKDM4ETDP1GAA | |
| SCHEMBL17095628 | 0.77 | ALDH1A1 (0.57) | ALDH1A1HTTKDM4ETDP1GAA | |
| SCHEMBL30334815 | 0.77 | ALDH1A1 (0.72) | ALDH1A1HTTKDM4EGAAHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240245670-A1 | DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | NOVARTIS AG (CH) | 2024-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240245670-A1 | DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | IKZF1, IKZF2, IKZF3 | ALDH1A1 2942/4885HTT 2083/4885KDM4E 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.